Takis

Takis is a leading biotechnology company dedicated to advancing cancer research and developing innovative therapies. Takis focuses on harnessing the power of the immune system to recognize and reject tumors as foreign entities. By offering cutting-edge technologies, Takis is committed to pioneering personalized cancer therapy based on deep insights into tumor biology.

Located at via di Castel Romano 100, Rome, 00128, IT, Takis collaborates with partners to identify new biomarkers and develop molecular diagnostic tests. The company's researchers excel in delivering genes in vivo through various technologies, including the electric transfer of genes (gene-electro-transfer–EGT), a technique with over a decade of proven success. This technology significantly enhances the tissue uptake of nucleic acids in vivo, leading to relevant immunological and antitumoral effects.

Takis engages with academic and industrial partners to study the effectiveness of innovative drugs and develop diagnostic tests. With its efficiency, speed of execution, and optimized operating costs, Takis is a partner of choice for advancing cancer research. We invite Takis's management team to create a customized and exclusive company showcase and product listing on our platform to further enhance their commercial development.